To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
Nonrandomized trial; follow-up, 4 to 29 months.
Academic tertiary referral medical center.
Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.
Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.
Clinical and radiographic comparisons before and after therapy.
Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.
OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.Arch Otolaryngol Head Neck Surg. 1996;122:1195-1199
Smith RJH, Burke DK, Sato Y, Poust RI, Kimura K, Bauman NM. OK-432 Therapy for Lymphangiomas. Arch Otolaryngol Head Neck Surg. 1996;122(11):1195–1199. doi:10.1001/archotol.1996.01890230041009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.